PA
CGNT icon

PharVision Advisers’s Cognyte Software CGNT Stock Holding History

PharVision Advisers’s Portfolio CGNT Stock Details CGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,706
Closed -$260K – 201
2025
Q4 		$260K Buy
27,706
+2,995
+12% +$25.9K 0.13% 368
2025
Q3 		$208K Buy
+24,711
New +$219K 0.12% 485

Other funds holding CGNT

EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
VB
Value Base Tel Aviv, Israel $127M AUM 12.37% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $2.55B AUM 104.35% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $368M AUM 42.67% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PharVision Advisers's CGNT Position: Q1 2026 in Review

PharVision Advisers sold out of Cognyte Software (CGNT) in Q1 2026, closing a stake of 27,706 shares — an estimated $260K sold.

PharVision Advisers first reported a position in CGNT in Q3 2025 and held it in 2 quarters. The position peaked at $260K in Q4 2025. 126 funds tracked by Wall St. Rank hold CGNT as of Q1 2026.

  • PharVision Advisers reported no remaining Cognyte Software position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 27,706 Cognyte Software shares in Q1 2026, an estimated $260K.
  • PharVision Advisers first reported a position in Cognyte Software in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Cognyte Software position peaked at $260K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Cognyte Software as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.